[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"type-b-aortic-dissection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:type-b-aortic-dissection":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,43,67,89,112,142,165],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100522777","improving-outcomes-in-vascular-disease---aortic-dissection-100522777",false,"NCT06087029","IMPRoving Outcomes in Vascular DisEase - Aortic Dissection","IMPRoving Outcomes in Vascular DisEase- Aortic Dissection","IMPROVE-AD","Inclusion Criteria:\n\n1. Age \\> 21 years\n2. Patients with a Stanford type B aortic dissection not involving the aorta at or proximal to the innominate artery, without rupture and\u002For malperfusion syndrome (renal, mesenteric, or extremity) who are within 48 hours to 6 weeks after start of index admission for their type B dissection\n3. Ability to provide written informed consent\n4. Investigator believes anatomy is suitable for TEVAR\n\nExclusion Criteria:\n\n1. Ongoing systemic infection\n2. Pregnant or planning to become pregnant in the next 3 months\n3. Life expectancy related to non-aortic conditions \\\u003C 2 years\n4. Unwilling or unable to comply with all study procedures\n5. Known patient history of genetic aortopathy\n6. Penetrating Aortic Ulcer without concomitant uTBAD\n7. Intramural hematoma without concomitant uTBAD\n8. Iatrogenic (traumatic) aortic dissection","ALL","21 Years",{"count":20,"type":21},1100,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to determine whether an upfront invasive strategy of TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause death or major aortic complications compared to an upfront conservative strategy of medical therapy with surveillance for deterioration in patients with uncomplicated type B aortic dissection.",[27],"Type B Aortic Dissection",[29],"TEVAR","RECRUITING","2026-04-28",{"date":33,"type":34},"2026-04-29","ACTUAL",{"date":36,"type":34},"2024-04-14",{"date":38,"type":21},"2030-06-30",{"name":40,"class":41},"Duke University","OTHER",63,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100634056","transcutaneous-auricular-vagus-nerve-stimulation-for-attenuation-of-inflammatory-response-and-blood-pressure-in-type-b-aortic-dissection-100634056","NCT07534722","Transcutaneous Auricular Vagus Nerve Stimulation for Attenuation of Inflammatory Response and Blood Pressure in Type B Aortic Dissection","taVNS for TBAD","Inclusion Criteria:\n\n1. Adults age 18 years and older.\n2. Presenting with acute, uncomplicated TBAD\n3. Ability to enroll within 24 hours of presentation\n\nExclusion Criteria:\n\n1. Prior Aortic Dissections\n2. Genetic aortpathies\n3. Iatrogenic aortic dissection related to prior procedure(s)","18 Years",{"count":52,"type":21},60,[24],"Patients with uncomplicated Type B aortic dissections (TBAD) are traditionally treated in the ICU for impulse control, with BP and HR goals. Local and systemic inflammation often is a resulting consequence of acute aortic dissection. Vagus nerve stimulation can impact hemodynamics and inflammation. This study will utilize a novel transcutaneous auricular vagus nerve stimulator (taVNS) as part of the treatment for patients with TBAD. It's hypothesized that vagus nerve stimulation may provide benefit to the acute TBAD population admitted to ICU by two distinct mechanisms:\n\n1. Through upregulation of parasympathetic pathways which may augment chemical heart rate and blood pressure control through bioelectric stimulation, and\n2. downregulation of inflammatory pathways through a neuro-immunological axis.",[27],"NOT_YET_RECRUITING","2026-04-15",{"date":59,"type":34},"2026-04-16",{"date":61,"type":21},"2026-04-17",{"date":63,"type":21},"2027-04-01",{"name":65,"class":41},"Washington University School of Medicine",1,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":74,"targetDuration":76,"studyType":77,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":4},"100594645","real-world-prospective-parallel-controlled-study-on-endovascular-therapy-for-improving-perfusion-and-remodeling-of-tbad-100594645","NCT07022145","Real-World Prospective Parallel Controlled Study on Endovascular Therapy for Improving Perfusion and Remodeling of TBAD","A Real-World Multicenter, Prospective, Non-Randomized Parallel Controlled Study on the Optimal Endovascular Therapy for Improving Distal Perfusion and Remodeling of Acute Type B Aortic Dissection","Inclusion Criteria:\n\n* Male participants aged ≥18 years or non-pregnant female participants\n* Diagnosed with acute complicated type B aortic dissection (defined as rupture\u002Fimminent rupture, associated ischemic syndromes \\[bowel, renal, or lower limb ischemia\\], radiologic progression of dissection or aortic dilation during hospitalization, uncontrolled hypertension, or refractory pain lasting over 12 hours), or high-risk type B dissection (defined as total aortic diameter \\>40 mm, false lumen diameter \\>22 mm, primary entry tear \\>10 mm, entry on the inner curvature, hemothorax, radiologic signs of ischemia \\[bowel, renal, or lower limb\\], or recurrent pain\u002Fsymptoms).\n* Patients deemed suitable for TEVAR or TEVAR combined with supra-aortic single-branch endovascular repair, as assessed by the investigator\n* Patients who understand the purpose of the study, voluntarily agree to participate by signing informed consent, and are willing to comply with follow-up requirements\n\nExclusion Criteria:\n\n* Subjects with hemodynamic instability or ruptured aortic dissection\n* Subjects who, due to anatomical factors, are unsuitable for isolated TEVAR or TEVAR combined with supra-aortic single-branch reconstruction\n* Subjects with connective tissue disorders, such as Marfan syndrome\n* Subjects in poor general condition who cannot tolerate general anesthesia\n* Subjects with known allergies to contrast agents or stent materials such as nitinol\n* Subjects with a life expectancy of less than 12 months\n* Subjects with a history of myocardial infarction or unstable angina within the past 3 months\n* Subjects with a history of TIA or cerebral infarction within the past 3 months\n* Subjects with serum creatinine levels \\>2.5 times the upper limit of normal or currently on dialysis\n* Subjects with severe comorbidities such as liver failure",{"count":75,"type":21},438,"5 Years","OBSERVATIONAL","There are both common and individual characteristics in patients with type B aortic dissection. Currently, for all subtypes of acute type B dissection, proximal endovascular repair is mostly performed during the subacute phase, while the distal dissection of the descending aorta is often managed with a \"watch and wait\" strategy. However, such a uniform approach carries potential risks, including imprecise indications, inappropriate timing, and uncertain prognosis. Our research team has previously established a comprehensive database and imaging repository of nearly 10,000 cases of type B dissection. Building upon existing subtypes-such as acute complicated, uncomplicated, penetrating atherosclerotic ulcer, and intramural hematoma-we have further explored refined classifications, including acute high-risk types and localized contrast enhancement of the aortic wall. For patients with different subtypes and at different stages of dissection-such as hyperacute, acute, or subacute-it is critical to develop individualized treatment strategies. These may include optimal medical therapy, isolated proximal endovascular repair, or combined proximal repair with distal bare stent implantation. Therefore, a large-scale clinical study is urgently needed to identify the optimal timing and approach for intervention based on refined classification schemes, and to establish personalized, stratified treatment strategies for different patient groups.\n\nThis project aims to conduct a real-world, prospective, multicenter, parallel-controlled study to compare outcomes between isolated proximal endovascular repair and combined proximal repair with distal bare stent implantation in patients with acute complicated or high-risk type B aortic dissection. The goal is to determine the most effective surgical approach for improving distal perfusion and promoting favorable aortic remodeling, thereby guiding treatment decision-making.",[27],"2025-06-07",{"date":82,"type":34},"2025-06-15",{"date":84,"type":21},"2025-06",{"date":86,"type":21},"2030-05",{"name":88,"class":41},"Shanghai Zhongshan Hospital",{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":100,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":66},"100593640","safety-and-efficacy-of-exercise-in-type-b-aortic-dissection-100593640","NCT07009067","Safety and Efficacy of Exercise in Type-B Aortic Dissection","Safety and Efficacy of Cardiac Rehabilitation With Exercise in Patients With Type-B Aortic Dissection and Intervention: Pilot Study","SECRET-Pilot","Inclusion Criteria:\n\n* Patients with a previous diagnosis of type B aortic dissection or intramural hematoma or penetrating ulcer, who underwent endovascular aortic repair (EVAR) or EVAR + supra-aortic shunt surgery for more than 1 month, and no related complications (such as endoleak, stent thrombosis, dissection progression, etc.) were found in the postoperative aortic CTA;\n* Able to independently carry out basic daily life activities, participants must be able to complete the baseline assessment and start the designated treatment;\n* Patients voluntarily participate in this study, sign the written informed consent, and are willing to cooperate with the follow-up;\n\nExclusion Criteria:\n\n* Acute myocardial infarction occurred 1 month ago;\n* Combined with severe aortic stenosis or regurgitation;\n* Combined with ascending aortic aneurysm or dissection;\n* Acute heart failure occurred 2 weeks ago;\n* Combined with severe hypertrophic obstructive cardiomyopathy;\n* Chronic renal failure stage 5, which is defined as glomerular filtration rate \\\u003C15ml\u002F(min·1.73m2) or dialysis;\n* During the screening examination, the patient's alanine aminotransferase or aspartate aminotransferase is greater than or equal to 5 times the upper limit of the normal value specified by our center;\n* Patients with any medical history that may affect compliance with the program;\n* Patients with severe language, mental or physical disabilities who are unable to participate in the program;\n* Pregnant or lactating women, or those with fertility who are unwilling\u002Funable to take effective contraceptive measures;\n* Patients participating in other interventional clinical trials;\n* Patients with long-term high-intensity exercise habits;\n* Patients who are judged by the researchers to be unsuitable for participation in this study;","75 Years",{"count":99,"type":21},20,[24],"This is a pilot study. The goal of this clinical trial is to evaluate the safety and efficacy of exercise-based cardiac rehabilitation in patients with Type-B Aortic dissection or intramural hematoma or penetrating ulcer and received endovascular repair. The main questions it aims to answer are:\n\n• Is exercise-based cardiac rehabilitation safe among these patients? Participants will be randomly assigned to receive usual care plus exercise-based cardiac rehabilitation (guided exercise for 3 months in rehabilitation center) or usual care.",[27],"2025-05-29",{"date":105,"type":34},"2025-06-06",{"date":107,"type":34},"2025-05-06",{"date":109,"type":21},"2028-12-31",{"name":111,"class":41},"Guangdong Provincial People's Hospital",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":122,"briefSummary":123,"conditions":124,"keywords":125,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":141},"100568008","extensive-multilayer-stent-treatment-in-aortic-dissection-100568008","NCT06675617","EXtensive mulTilayer stEnt treatmeNt in Aortic disSectiOn","A Clinical Study to Evaluate the Effectiveness and Safety of the Allay® Aortic Stent as Adjunctive Endovascular Treatment of Type B Aortic Dissection in Patients Eligible for Thoracic Endovascular Repair With Stent Grafts","EXTENSO","Inclusion Criteria:\n\n* Have a type B aortic dissection extending to the celiac trunk or beyond\n* Are eligible for thoracic endovascular treatment with stent grafts as per local guidelines, and physician's decision\n* Have been elected for treatment with commercially available stent graft as per their IFU within 90 days of dissection symptoms onset\n\nExclusion Criteria:\n\n* General Exclusion Criteria:\n\n  * Age \\\u003C 18 years\n  * Pregnant, breast-feeding or planning on becoming pregnant during the entire duration of the study\n  * Unable to provide written informed consent\n  * Unable or unwilling to comply with the requirements of the study protocol\n  * Taking part already in an investigational device or drug study that could interfere with the outcomes being studied\n  * Active drug addiction or known history of drug abuse within one year of treatment\n* Medical Exclusion Criteria:\n\n  * Aortic rupture, free or contained including haemothorax, increasing periaortic hematoma, or mediastinal hematoma\n  * Aortic fistula\n  * Suspicion of bowel necrosis or irreversible visceral ischemia\n  * Stage 5 chronic kidney disease\n  * Life expectancy of less than 2 years due to any other medical condition than the dissection to be treated\n  * Active malignancy\n  * Known sensitivities or allergies to the device materials (including cobalt, chromium, nickel)\n  * Known sensitivities or allergies to contrast materials that cannot be pre-medicated\n  * Mycotic aortic aneurysm or active systemic infection that may place the patient at increased risk of endovascular infection\n  * American Society of Anaesthesiologists (ASA) class V (moribund patient not expected to live 24 hours with or without operation)\n  * Diagnosed or suspected congenital degenerative connective tissue disease (e.g., Marfan's, Loeys-Dietz or Ehlers-Danlos syndrome)\n  * Uncorrectable coagulopathy, bleeding diathesis or refusal of blood transfusion\n  * Any major cardiovascular or cerebrovascular ischemic event, including myocardial infarction or stroke, or treatment of such event, within 90 days prior to enrolment\n  * Any aortic-related interventional or surgical procedure within 30 days prior to enrolment\n  * Any planned aortic-related interventional or surgical procedure within 30 days after the study procedure\n* Anatomical Exclusion Criteria:\n\n  * Aneurysmal dilatation of the false lumen defined as maximum transaortic diameter \\>55 mm in women or \\>60 mm in men in the thoraco-abdominal segment or \\>50 mm in women or \\>55 mm in men in the abdominal segment, measured inner-wall to inner-wall;\n  * Inadequate proximal landing zone for the stent graft, such zone being \\\u003C20 mm long\n  * Inadequate proximal landing zone geometry for the Allay® Aortic Stent (e.g. aortic kink)\n  * Planned implantation of a stent graft with a distal diameter \\>38 mm or \\\u003C20 mm\n  * Aorta or iliac anatomy not allowing the advancement of the delivery system\n  * Subject in whom the thoracic stent graft is either 1) not implanted in its intended position and\u002For 2) leads to any serious device complication, and\u002For who has 3) persistent static obstruction of the visceral or both renal arteries, prior to Allay® Aortic Stent implantation, will not be implanted with the Allay® Aortic Stent and will be withdrawn from the study",{"count":121,"type":21},72,[24],"This clinical trial is a prospective, multicenter, open label study designed to evaluate the effectiveness and the safety of the Allay® Aortic Stent as adjunctive endovascular treatment of Type B aortic dissection in patients eligible for thoracic endovascular aortic repair with stent grafts.",[27],[126,127,128,129,130],"TBAD","Allay","aortic","dissection","type B","2025-05-16",{"date":133,"type":34},"2025-05-18",{"date":135,"type":34},"2024-10-30",{"date":137,"type":21},"2031-06",{"name":139,"class":140},"Intressa Vascular SA","INDUSTRY",10,{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":152,"conditions":153,"keywords":154,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":4},"100572999","conventional-tevar-versus-fabulous-rct-100572999","NCT06740565","Conventional TEVAR Versus FABULOUS RCT","A Multicenter, Prospective, Randomized Control Study on the Optimal Intervention Approach for High-risk Type B Aortic Dissection","Inclusion Criteria:\n\n* Males aged 18 years or older, or non-pregnant females\n\n  * Diagnosed with high-risk Type B aortic dissection with a narrow true lumen (defined as the minimum true lumen diameter being less than 30% of the total vessel diameter) and\u002For poor radiographic or clinical visceral perfusion (including abnormal blood supply to the liver, kidneys, mesentery, or lower limb ischemia)\n  * Deemed suitable for endovascular treatment according to the investigator's judgment\n  * Able to understand the purpose of the trial, willing to participate voluntarily and sign the informed consent form, and committed to follow-up visits.\n\nExclusion Criteria:\n\n* • Subjects with hemodynamic instability or ruptured aortic dissection\n\n  * Subjects who, due to various anatomical factors, are unable to undergo TEVAR alone\n  * Subjects with connective tissue diseases, such as Marfan syndrome\n  * Subjects in poor general condition, unable to tolerate general anesthesia\n  * Subjects allergic to contrast agents, nitinol stent materials, or other stent components\n  * Subjects with a life expectancy of less than 12 months\n  * Subjects with a history of myocardial infarction or unstable angina within the past 3 months\n  * Subjects with a history of TIA or cerebral infarction within the past 3 months\n  * Subjects with creatinine levels exceeding 2.5 times the upper normal limit or those currently on dialysis\n  * Subjects with severe conditions such as liver failure",{"count":150,"type":21},392,[24],"For High-risk Type B aortic dissections, a multicenter, prospective, randomized controlled study is conducted to compare the clinical outcomes of conventional proximal endovascular repair (TEVAR) alone versus the Fabulous system which includes a proximal stent graft with a distal bare metal stent implanted. The study aims to determine the optimal intervention method for such population.",[27],[155,156],"endovascular repair","distal bare stent","2024-12-15",{"date":159,"type":34},"2024-12-18",{"date":161,"type":21},"2025-02-01",{"date":163,"type":21},"2029-02-01",{"name":88,"class":41},{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":174,"briefSummary":175,"conditions":176,"keywords":180,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":193},"100476082","evaluation-of-the-valiant-captivia-physician-fenestrated-stent-graft-system-in-aortic-arch-and-descending-thoracic-aorta-pathologies-100476082","NCT05479305","Evaluation of the Valiant Captivia Physician Fenestrated Stent Graft System in Aortic Arch and Descending Thoracic Aorta Pathologies","EVERGREEN","Inclusion Criteria:\n\nTAA\u002FPAU (Thoracic Aortic Aneurysms and Penetrating Ulcers):\n\n1. Subject is at least 18 years of age.\n2. Subject understands and has signed an Informed Consent approved by the Sponsor for this study.\n3. Subject must be considered a candidate for revascularisation of BT, LCCA and LSA.\n4. Subject must be able to tolerate surgical revascularisation of BT, LCCA and LSA.\n5. Subject has a TAA\u002FPAU which is:\n\n   * a fusiform aneurysm with a diameter of ≥ 5.5 cm OR is \\> 2 times the diameter of the non-aneurysmal thoracic aorta; AND\u002FOR\n   * a saccular aneurysm or PAU (ulcer defined as ≥ 10 mm in depth and 20 mm in diameter, or symptomatic)\n6. Subject has a healthy, non-diseased aortic proximal seal zone of at least 20 mm\n7. Subject has no thrombus in the proximal neck\n8. Subject has a non-diseased aortic diameter between 25 mm and 42 mm and max diameter of the ascending aorta is ≤ 40 mm\n9. Subject has a non-diseased LSA which is eligible for stent-grafting\n10. Subject has sufficient landing zone within the LSA to accommodate the stent-graft without occlusion of any significant vessels\n11. Brachial, iliac or femoral artery access vessel morphology (diameter, calcification, tortuosity) that is compatible with vascular access techniques, the device, or accessories.\n12. Symptomatic patient who needs semi urgent repair; aptient is at high surgical risk and cannot wait for 6-8 weeks for a custom-made stent graft\n13. Subject is affiliated with the social security system\n\nInclusion criteria:\n\nTBAD(Type B Dissections) and Residual dissection after Type A repair:\n\n1. Subject is at least 18 years of age.\n2. Subject understands and has signed an Informed Consent approved by the Sponsor for this study.\n3. a) Subject has a degenerative aortic arch aneurysm which will require coverage of the LSA and extension of the proximal seal zone to zone 0 And\u002For b) Subject has a complicated TBAD (acute, subacute or chronic) which will require coverage of the LSA and extension of the proximal seal zone to zone 0 And\u002For c) Subject has a complicated residual dissection after replacement of the ascending aorta for type A aortic dissection which will require coverage of the LSA and extension of the proximal seal zone to zone 0\n4. Subject has a healthy, non-diseased (without thrombus) aortic proximal seal zone of at least 20 mm\n5. Subject has a healthy, non-diseased (without thrombus) aortic distal seal zone of at least 20 mm\n6. Subject has a maximum diameter of the distal ascending aorta just above the BT of 40 mm\n7. Subject has a non-diseased aortic diameter between 28 mm to 42 mm and the ascending aorta ≤ 40 m\n8. Subject has a no atheromatous lesions int the arch and the BT, LCCA and LSA\n9. Brachial, iliac or femoral artery access vessel morphology (diameter, calcification, tortuosity) that is compatible with vascular access techniques, the device, or accessories\n10. Symptomatic patient who needs semi urgent repair; aptient is at high surgical risk and cannot wait for 6-8 weeks for a custom-made stent graft\n11. Subject is affiliated with the social security system\n\nExclusion Criteria:\n\n(Thoracic Aortic Aneurysms and Penetrating Ulcers, TAA\u002FPAU):\n\n1. Subject has an aneurysmal, tortuous, or atherosclerotic LSA.\n2. Subject has an aneurysmal, tortuous, or atherosclerotic LCCA.\n3. Subject has an aneurysmal, tortuous, or atherosclerotic BT.\n4. Subject has an ascending aorta diameter \\> 40 mm\n5. Subject has thrombus in the proximal neck\n6. Subject has an emergent need of treatment of the aortic pathology\n7. Subject has prohibitive calcification, occlusive disease, or tortuosity of intended sealing sites\n8. Subject has circumferential calcification in the common femoral or external iliac artery or in the common iliac artery with an intraluminal diameter (ID) less than 9 mm at any point proximal to or at the access vessel site unless a surgical adjunctive procedure is planned.\n9. Subject has an aortic atheroma classified as grade IV or grade V.\n10. Subject has had previous endovascular repair of the ascending\n11. Subject has significant and\u002For circumferential aortic mural thrombus at either the proximal or distal attachment sites that would compromise sealing of the device.\n12. Subject is pregnant\n13. Subject has a known allergy or intolerance to the device components.\n14. Subject is in acute renal failure\n15. Subject has a body habitus which prevents adequate visualisation of the aorta.\n16. Subject has coronary artery disease with unstable angina and who has not received treatment.\n17. Subject has a connective tissue disease (e.g. Marfan's syndrome, medial degeneration).\n18. Subject has active systemic infection and\u002For a mycotic aneurysm.\n19. Subject is currently participating in an investigational drug or device clinical trial that would interfere with the observations of this study.\n20. Subject has other medical, social, or psychological problems that, in the opinion of the investigator, will interfere with treatment and follow-up procedures.\n21. Subject has a life expectancy of less than 2 years year.\n22. Subject requires treatment of an infrarenal aneurysm at the time of the implantation.\n23. Subject has had previous surgical or endovascular treatment of an infra-renal aortic aneurysm \\\u003C30 days of implantation of investigational device.\n24. Subject has a history of bleeding diathesis, coagulopathy, or refuses blood transfusion.\n25. Subject has had a cerebral vascular accident (CVA) within 3 months.\n26. Subject has had a myocardial infarction (MI) within 3 months.\n27. Subject has a known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment\n\nExclusion criteria:\n\n(Type B Dissections, TBAD and residual dissection after Type A repair):\n\n1. Subject has an aneurysmal, tortuous, or atherosclerotic LCCA.\n2. Subject has an aneurysmal, tortuous, or atherosclerotic LSA.\n3. Subject has an aneurysmal, tortuous, or atherosclerotic BT.\n4. Subject has a dissected BT and or LCCA\n5. Subject has prohibitive calcification, occlusive disease, or tortuosity of intended sealing sites.\n6. Subject has circumferential calcification in the common femoral artery, external iliac artery or in the common iliac artery with an intraluminal diameter (ID) less than 9 mm at any point proximal to or at the access vessel site unless a surgical adjunctive procedure is planned.\n7. Subject has an aortic atheroma classified as grade IV or grade V.\n8. Subject has had previous endovascular repair of the ascending, arch\n9. Subject has significant and\u002For circumferential aortic mural thrombus at either the proximal or distal sealing sites that would compromise seal of the device\n10. Subject is pregnant\n11. Subject has a known allergy or intolerance to the device components\n12. Subject is in acute renal failure\n13. Subject has a body habitus which prevents adequate visualisation of the aorta.\n14. Subject has coronary artery disease with unstable angina and who has not received treatment.\n15. Subject has a connective tissue disease (e.g. Marfan's syndrome, medial degeneration).\n16. Subject has active systemic infection and\u002For a mycotic aneurysm.\n17. Subject is currently participating in an investigational drug or device clinical trial that would interfere with the observationsof this study\n18. Subject has other medical, social, or psychological problems that, in the opinion of the investigator, will interfere with treatment and follow-up procedures.\n19. Subject has a life expectancy of less than 2 years.\n20. Subject requires treatment of an infrarenal aneurysm at the time of the implantation.\n21. Subject has had previous surgical or endovascular treatment of an infra-renal aortic aneurysm \\\u003C30 days of implantation of investigational device.\n22. Subject has a history of bleeding diathesis, coagulopathy, or refuses blood transfusion.\n23. Subject has had a cerebral vascular accident (CVA) within 3 months.\n24. Subject has had a myocardial infarction (MI) within 3 months.\n25. Subject has a known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment.\n\n    \\-",{"count":173,"type":21},30,[24],"The study objectives are to assess safety and effectiveness, measured acutely and at the 30-day visit after implantation of the Valiant Captivia physician fenestrated Stent Graft.\n\nClinical utility measures throughout the procedure and until discharge will be assessed",[177,178,27,179],"Penetrating Ulcer of Aorta","Aneurysm Aortic","Residual Dissection After Type A Repair",[181,182,183],"aortic arch","descending thoracic aorta","valiant captivia stent graft","2024-04-30",{"date":186,"type":34},"2024-05-01",{"date":188,"type":34},"2023-11-21",{"date":190,"type":21},"2027-10",{"name":192,"class":140},"Ceric Sàrl",4]